Herceptin, Trastuzumab Newswire (Page 4)

Herceptin, Trastuzumab Newswire (Page 4)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 4)

Results 61 - 80 of 813 in Herceptin, Trastuzumab (generic)

  1. Protein Drugs Market Current Trends and Future Aspect Analysis 2019Read the original story w/Photo

    Feb 12, 2018 | SBWire

    The pharmaceutical industry is witnessing a shift in focus from molecular drugs to protein based drugs due to its high specificity, enhanced efficacy, affinity, solubility, and low incidences of toxicity. The market for protein drugs is segmented into antibody drugs, peptide hormones, blood products and enzymes market.

    Comment?

  2. JHL Logo High ResolutionRead the original story w/Photo

    Feb 3, 2018 | PR Newswire

    JHL's Board of Directors believes the voluntary delisting is in the best interests of the company and its shareholders because it enables JHL to pursue planned expansion activities and to explore various fundraising strategies, including potentially listing on an overseas exchange. About JHL Biotech JHL Biotech, Inc. is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations.

    Comment?

  3. Trastuzumab Biosimilar Demonstrates EquivalenceRead the original story w/Photo

    Feb 8, 2018 | JD Supra

    The Journal of Clinical Oncology reported that Merck and Samsung Bioepis' biosimilar to trastuzumab , SB3, demonstrated equivalence to trastuzumab in recent Phase III trials. According to the report, in a phase III, randomized, double-blind study of 800 women with HER2-positive breast cancer, SB3 induced a rate of breast pathologic complete response that was similar to trastuzumab.

    Comment?

  4. New hope for cancer patientsRead the original story w/Photo

    Feb 4, 2018 | The Daily Star

    World Cancer Day is the one singular initiative under which the entire world can unite together in the fight against the global cancer epidemic. It takes place every year on February 4. Immunotherapy and targeted therapy give patients more options in the battle against gastrointestinal cancers.

    Comment?

  5. Financial Comparison: Charles River Laboratories Intl.Read the original story w/Photo

    Feb 3, 2018 | The Breeze

    Charles River Laboratories Intl. and Oncobiologics are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

    Comment?

  6. JHL Biotech's Application to Voluntarily Terminate Trading of Shares Approved by Taipei ExchangeRead the original story w/Photo

    Feb 1, 2018 | PR Newswire

    JHL had submitted an application to voluntarily delist from TPEx. JHL's Board of Directors believes this is in the best interests of the company and its shareholders because it enables JHL to pursue planned expansion activities and to explore various fundraising strategies .

    Comment?

  7. Breast cancer drug approved for NHS in EnglandRead the original story

    Feb 2, 2018 | PressReleasePoint

    The National Institute for Health and Care Excellence issued its final decision, recommending pertuzumab for some women with breast cancer. Emlyn Samuel from Cancer Research UK said the decision was good news and that the "breakthrough drug" provides an important treatment option.

    Comment?

  8. Longitudinal autoantibody responses against tumor-associated antigens ...Read the original story w/Photo

    Jan 30, 2018 | BioMed Central

    Metastatic breast cancer is most often diagnosed months after completion of treatment of the primary tumor when a patient reports physical symptoms. Besides a physical examination, no other alternative recurrence screening method is recommended for routine follow-up care.

    Comment?

  9. A retrospective study of the safety and efficacy of paclitaxel plus...Read the original story w/Photo

    Jan 30, 2018 | BioMed Central

    Ramucirumab has recently proved to be effective for advanced or recurrent gastric cancer . Ascites and peritoneal metastasis are among the most common complications of AGC.

    Comment?

  10. Biosimilar Monoclonal Antibodies Market to Reach to USD 8.97 Billion by 2023Read the original story

    Jan 31, 2018 | SBWire

    The global biosimlar monoclonal antibodies market is projected to grow at a CAGR of 42.8% over the period of 2017 to 2023 and reach to USD 8.97 billion by the end of 2023, states Infinium Global Research in its new report on global biosimilar monoclonal antibodies market. The report also identifies that with an expiry of several blockbuster drugs several biosimilar drugs to experience significant opportunities over the next few years.

    Comment?

  11. Seattle Genetics Snaps Up Cascadian in $614M Buyout DealRead the original story w/Photo

    Jan 30, 2018 | BioSpace

    Jan. 31, 2018 11:30 UTC Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline BOTHELL, Wash. & SEATTLE-- -- Seattle Genetics and Cascadian Therapeutics today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics.

    Comment?

  12. Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage ...Read the original story

    Jan 31, 2018 | Customer Interaction Solutions

    Seattle Genetics, Inc. and Cascadian Therapeutics, Inc. today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximately $614 million.

    Comment?

  13. Cascadian Therapeutics: Shares Will Continue To Climb In 2018Read the original story w/Photo

    Jan 30, 2018 | Seeking Alpha

    The stock has risen by over 40% since I stated that it was "worth much more than the present share price". The EMA setback for Puma Biotechnology's neratinib serves to highlight the differentiated profile of tucatinib and the possibility of becoming a favored HER-2 targeted agent if it reaches approval.

    Comment?

  14. Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635Read the original story w/Photo

    Jan 29, 2018 | Business Wire

    The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The stock option vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of January 2, 2018 and one-thirty-sixth of the shares underlying the award vesting on each monthly anniversary thereafter, subject to Mr. Hunt's continued employment with the Company.

    Comment?

  15. Fake medicines? Face 15 year jail termRead the original story w/Photo

    Jan 29, 2018 | EurActiv.com

    Twenty-one EU countries have made falsifying medicines a criminal offence, carrying a potential jail sentence of 15 years, according to a new report published on Friday by the European Commission. Maximum prison sentences for the falsification of medicines range from one year in Sweden, Finland and Greece to 15 years in Austria, Slovenia and Slovakia.

    Comment?

  16. Head-To-Head Comparison: OncobiologicsRead the original story w/Photo

    Jan 29, 2018 | AmericanBankingNews.com

    Oncobiologics and Charles River Laboratories Intl. are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

    Comment?

  17. Critical Review: OncobiologicsRead the original story w/Photo

    Jan 29, 2018 | IntersportsWire

    Oncobiologics and Intrexon are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends. Oncobiologics has higher earnings, but lower revenue than Intrexon.

    Comment?

  18. As scientists train the immune system to fight cancer, others...Read the original story w/Photo

    Jan 28, 2018 | Albany Times Union

    For decades now, these have been the only weapons available in the war against cancer. But everyone who has known cancer up close patients, their loved ones and physicians has longed for a better way.

    Comment?

  19. Merus: Important Catalysts In 2018Read the original story w/Photo

    Jan 26, 2018 | Seeking Alpha

    Readers who have done their due diligence and are interested in the story should purchase a pilot position in the near term. Shares of Netherlands-based biotech Merus have finished slightly negative since I called the stock a Buy after a lucrative partnership with Incyte Corporation was inked last year.

    Comment?

  20. New BPCIA Litigations Regarding Celltrion's Trastuzumab and Rituximab BiosimilarsRead the original story w/Photo

    Jan 26, 2018 | JD Supra

    On January 11, 2018, Celltrion and Teva filed two lawsuits against Genentech in the District Court for the Northern District of California. Case No.

    Comment?